Latvija - latviešu - Zāļu valsts aģentūra

teva b.v., netherlands - telmisartanum, hydrochlorothiazidum - tablete - 80 mg/12,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 50 mg/12,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 100 mg/12,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

stada arzneimittel ag, germany - losartanum kalicum, hydrochlorothiazidum - apvalkotā tablete - 100 mg/25 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - irbesartan, hydrochlorothiazide - hipertensija - agents, kas iedarbojas uz renīna-angiotenzīna sistēmu - esenciālas hipertensijas ārstēšana. Šī fiksētas devas kombinācija nav norādīts pieaugušiem pacientiem, kuru asinsspiedienu nevar pienācīgi kontrolēt par irbesartan vai hydrochlorothiazide atsevišķi (skatīt 5. iedaļu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklīdu attēlveidošana - terapeitiskie radiofarmaceitiskie preparāti - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 160 mg/25 mg